Cyclosporine

Generic Name: Cyclosporine

Brand Names: Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis

Drug Type: Small Molecule

Chemical Formula: C_₆₂H_₁₁₁N_₁₁O_₁₂

CAS Number: 59865-13-3

Unique Ingredient Identifier: 83HN0GTJ6D

Background: Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...

Indication: Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...

Associated Conditions: Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production

Associated Therapies: -

Clinical Trials

Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia

Phase 3

Terminated

Conditions: Leukemia

Interventions: Drug: cyclophosphamide
Drug: etoposide
Drug: cyclosporine
Procedure: allogeneic bone marrow transplantation
Radiation: Total Body Irradiation
Drug: methotrexate
Radiation: Radiation
Drug: Busulfan
Drug: Mesna

First Posted Date: 2004-05-19

Last Posted Date: 2013-10-16

Lead Sponsor: Children's Hospital of Philadelphia

Target Recruit Count: 43

Registration Number: NCT00002961

Locations: 🇺🇸
Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States
🇺🇸
Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸
Children's Mercy Hospital, Kansas City, Missouri, United States

and more 15 locations

Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

Phase 1

Completed

Conditions: Graft Versus Host Disease
Leukemia
Lymphoma
Myelodysplastic Syndromes
Myeloma

Interventions: Drug: cyclophosphamide
Drug: cyclosporine
Drug: leucovorin calcium
Drug: methotrexate
Drug: methylprednisolone
Procedure: in vitro-treated bone marrow transplantation
Radiation: radiation therapy

First Posted Date: 2004-05-03

Last Posted Date: 2017-04-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT00005988

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: cyclosporine
Drug: CPT-11

First Posted Date: 2004-04-27

Last Posted Date: 2014-03-07

Lead Sponsor: University of Chicago

Target Recruit Count: 16

Registration Number: NCT00003950

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

and more 7 locations

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Myelodysplastic Syndromes
Multiple Myeloma and Plasma Cell Neoplasm
Graft Versus Host Disease
Leukemia
Lymphoma

Interventions: Biological: anti-thymocyte globulin
Biological: filgrastim
Drug: busulfan
Drug: cyclophosphamide
Drug: cyclosporine
Drug: methylprednisolone
Procedure: bone marrow ablation with stem cell support
Procedure: umbilical cord blood transplantation
Radiation: radiation therapy

First Posted Date: 2004-04-27

Last Posted Date: 2019-12-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00003270

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation

Phase 3

Completed

Conditions: Graft Versus Host Disease
Leukemia
Lymphoma

First Posted Date: 2004-04-26

Last Posted Date: 2011-11-30

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00002456

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Phase 1

Completed

Conditions: Stage I Multiple Myeloma
Stage II Multiple Myeloma
Refractory Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: melphalan
Procedure: autologous hematopoietic stem cell transplantation
Procedure: autologous bone marrow transplantation
Procedure: peripheral blood stem cell transplantation
Radiation: total-body irradiation
Drug: cyclosporine
Drug: mycophenolate mofetil
Biological: therapeutic allogeneic lymphocytes

First Posted Date: 2004-04-15

Last Posted Date: 2020-02-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00003954

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

and more 1 locations

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2004-04-08

Last Posted Date: 2012-03-08

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 20

Registration Number: NCT00080925

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Phase 2

Withdrawn

Conditions: Myelodysplastic Syndromes
Graft Versus Host Disease
Leukemia

First Posted Date: 2004-04-08

Last Posted Date: 2014-12-04

Lead Sponsor: Mesoblast International Sàrl

Registration Number: NCT00081055

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Not Applicable

Completed

Conditions: Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Childhood Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Childhood Renal Cell Carcinoma
Chronic Phase Chronic Myelogenous Leukemia
Clear Cell Renal Cell Carcinoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Adult Acute Myeloid Leukemia With Del(5q)

Interventions: Drug: fludarabine phosphate
Radiation: total-body irradiation
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Procedure: allogeneic bone marrow transplantation
Procedure: peripheral blood stem cell transplantation
Biological: therapeutic allogeneic lymphocytes
Drug: cyclosporine
Drug: mycophenolate mofetil
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2004-04-02

Last Posted Date: 2019-09-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 55

Registration Number: NCT00005799

Locations: 🇩🇪
Universitaet Leipzig, Leipzig, Germany
🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States

and more 4 locations

Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Drug/Agent Toxicity by Tissue/Organ
Lymphoma
Neutropenia
Small Intestine Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: cyclosporine
Drug: irinotecan hydrochloride
Drug: phenobarbital

First Posted Date: 2004-03-26

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT00002759

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy